Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancer

Annals of the New York Academy of Sciences

Volumn 1210, Issue 1, 2010, Pages 86-92

  Oliveras, G ^a   Blancafort, A ^a   Urruticoechea, A ^b   Campuzano, O ^a   Gomez Cabello D ^c   Brugada, R ^a   Lopez Rodriguez M L ^d   Colomer, R ^c   Puig, T ^a  

^a GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c MD ANDERSON CANCER CENTER   (Spain)

^d UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Breast cancer; Fatty acid synthase (FASN); HER2; Novel anti FASN compounds; Preclinical study

Indexed keywords

2,3 EPOXI 4 OXO 7,10 DODECADIENOXYLAMIDE; ANTINEOPLASTIC AGENT; AU 565; C 75; C 93; CARNITINE PALMITOYLTRANSFERASE I; CERULENIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIGALLOCATECHIN GALLATE; FATTY ACID SYNTHASE; FATTY ACID SYNTHASE INHIBITOR; FLAVONOID; G 28 UCM; HYPOXIA INDUCIBLE FACTOR 1; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MYCOTOXIN; PHOSPHATIDYLINOSITOL 3 KINASE; POLYPHENOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; STEROL REGULATORY ELEMENT BINDING PROTEIN; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; CATECHIN; DRUG DERIVATIVE; HER2 PROTEIN, HUMAN;

ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CELL SURVIVAL; DNA SYNTHESIS; DRUG BIOAVAILABILITY; DRUG STRUCTURE; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVITY; ENZYME REGULATION; FATTY ACID OXIDATION; GENE AMPLIFICATION; GENE EXPRESSION; HOMEOSTASIS; HUMAN; IMMUNOHISTOCHEMISTRY; LIPOGENESIS; NONHUMAN; PROSTATE CANCER; PROTEIN BINDING; PROTEIN STABILITY; SIGNAL TRANSDUCTION; TUMOR VOLUME; BREAST TUMOR; DRUG ANTAGONISM; DRUG EFFECT; FEMALE; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROGNOSIS;

ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CATECHIN; CELL SURVIVAL; FATTY ACID SYNTHETASE COMPLEX; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROGNOSIS; RECEPTOR, ERBB-2;

EID: 78349257052     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05777.x     Document Type: Article

References (41)

1. Clemens, M.J. 2004. Targets and mechanisms for the regulation of translation in malignant transformation. Oncogene 23: 3180-3188.
2. Warburg, O. 1956. On the origin of cancer cells. Science 123: 309-314.
3. Kuhajda, F.P. 2000. Fatty-acid Synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 16: 202-208.
4. Kuhajda, F.P. 2006. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res. 66: 5977-5980.
5. Milgraum, F.P., L.A. Witters, G.R. Pasternack & F.P. Kuhajda 1997. Enzymes of the fatty acid synthesis pathway are highly expressed in situ breast carcinoma. Clin. Cancer Res. 3: 2115-2120.
6. Swinnen, J.V., K. Brusselmans & G. Verhoeven 2006. Increased lipogenesis in cancer cells: new players, novel targets. Curr. Opin. Clin. Nutr. Metab. Care. 9: 358-365.
7. Thupari, J.N., M.L. Pinn & F.P. Kuhajda 2001. Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem. Biophys. Res. Commun. 285: 217-223.
8. Brusselmans, K., E. De Schrijver, G. Verhoeven & J.V. Swinnen 2005. RNA interference mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res. 65: 6719-6725.
9. Smith, S. 1994. The animal fatty acid synthase: one gene, one polypeptide, seven enzymes. FASEB J. 8: 1248-1259.
10. Little, J.L. & S.J. Kridel 2008. Fatty acid synthase activity in tumor cells. Subcell. Biochem. 49: 169-194.
11. Kusakabe, T., M. Maeda, N. Hoshi, et al 2000. Fatty acid synthase is expressed mainly in adult hormone-sensitive cells or cells with high lipid metabolism and in proliferating fetal cells. Histochem. Cytochem. 48: 613-622.
12. López, M., C.J. Lelliott & A. Vidal-Puig 2007. Hypothalamic fatty acid metabolism: a housekeeping pathway that regulates food intake. Bioessays 29: 248-261.
13. Weiss, L., G.E. Hoffmann, R. Schreiber, et al 1986. Fatty-acid biosynthesis in man, a pathway of minor importance: purification, optimal assay conditions, and organ distribution of fatty-acid synthase. Biol. Chem. Hoppe Seyler 367: 905-912.
14. Porstmann, T., B. Griffiths, Y.L. Chung, et al 2005. PKB/Akt induces transcription of enzymes involved in cholesterol and fatty acid biosynthesis via activation of SREBP. Oncogene 24: 6465-6481.
15. Medes, G., A. Thomas & S. Weinhouse 1953. Metabolism of neoplastic tissue IV: a study of lipid synthesis in neoplastic tissue slices in vitro. Cancer Res. 13: 27-29.
16. Szutowicz, A., J. Kwiatkowski & S. Angielski 1979. Lipogenetic and glycolytic enzyme activities in carcinoma and non-malignant diseases of the human breast. Br. J. Cancer 39: 681-687.
17. Menendez, J.A. & R. Lupu 2007. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat. Rev. Cancer 7: 763-777.
18. Visca, P., V. Sebastiani, C. Botti, et al 2004. Fatty acid synthase (FASN) is a marker of increased risk of recurrence in lung carcinoma. Anticancer Res. 24: 4169-4173.
19. Puig, T., R. Porta & R. Colomer 2009. Fatty acid synthase: a new anti-tumor target. Med. Clin. 132: 359-363.
20. Wang, Y., F.P. Kuhajda, J.N. Li, et al 2001. Fatty acid synthase (FASN) expression in human breast cancer cell culture supernatants and in breast cancer patients. Cancer Lett. 167: 99-104.
21. Bandyopadhyay, S., S.K. Pai, M. Watabe, et al 2005. FASN expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FASN siRNA to induce apoptosis. Oncogene 24: 5389-5395.
22. Zhang, D., L.K. Tai, L.L. Wong, et al 2005. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER2/neupositive breast cancer. Mol. Cell Proteomics 4: 1686-1696.
23. Wang, Y., F.P. Kuhajda, L.J. Sokoll & D.W. Chan 2001. Two-site ELISA for the quantitative determination of fatty acid synthase. Clin. Chim. Acta. 304: 107-115.
24. Liu, X., Y. Shi, V.L. Giranda & Y. Luo 2006. Inhibition of the phosphatidylinositol 3-kinase/Akt pathway sensitizes MDA MB468 human breast cancer cells to cerulenin-induced apoptosis. Mol. Cancer Ther. 5: 494-501.
25. Pizer, E.S., C. Jackisch, F.D. Wood, et al 1996. Inhibition of fatty acid synthesis induces programmed cell death in human breast cancer cells. Cancer Res. 56: 2745-2747.
26. Little, J.L., F.B. Wheeler, D.R. Fels, et al 2007. Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Res. 67: 1262-1269.
27. Fiorentino, M., G. Zadra, E. Palescandolo, et al 2008. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab. Invest. 88: 1340-1348.
28. Kuhajda, F.P., E.S. Pizer, J.N. Li, et al 2000. Synthesis and antitumor activity of an inhibitor of fatty acid synthase. Proc. Natl. Acad. Sci. USA 97: 3450-3454.
29. Wortman, M.D., D.J. Clegg, D. D'Alessio, et al 2003. C75 inhibits food intake by increasing CNS glucose metabolism. Nat. Med. 9: 483-485.
30. Orita, H., J. Coulter, C. Lemmon, et al 2007. Selective inhibition of fatty acid synthase for lung cancer treatment. Clin. Cancer Res. 13: 7139-7145.
31. Orita, H., J. Coulter, E. Tully, et al 2008. Inhibiting fatty acid synthase for chemoprevention of chemically induced lung tumors. Clin. Cancer Res. 14: 2458-2464.
32. Kridel, S.J., F. Axelrod, N. Rozenkrantz & J.W. Smith 2004. Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity. Cancer Res. 64: 2070-2075.
33. Menendez, J.A., L. Vellon & R. Lupu 2005. Orlistat: from antiobesity drug to anticancer agent in Her-2/neu (erbB-2)-overexpressing gastrointestinal tumors? Exp. Biol. Med. 230: 151-154.
34. Browne, C.D., E.J. Hindmarsh & J.W. Smith 2006. Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor. FASEB J. 20: 2027-2035.
35. Lin, J.K. & S.Y. Lin-Shiau 2006. Mechanisms of hypolipidemic and anti-obesity effects of tea and tea polyphenols. Mol. Nutr. Food Res. 50: 211-217.
36. Jatoi, A., N. Ellison, P.A. Burch, et al 2003. A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. Cancer 97: 1442-1446.
37. Puig, T., A. Vázquez-Martín, J. Relat, et al 2008. Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. Breast Cancer Res. Treat. 109: 471-479.
38. Puig, T., J. Relat, P.F. Marrero, et al 2008. Green tea catechin inhibits fatty acid synthase without stimulating carnitine palmitoyltransferase-1 or inducing weight loss in experimental animals. Anticancer Res. 28: 3671-3676.
39. Colomer, R., T. Puig, J. Brunet, et al 2007. Novel polyhydroxylated compounds as fatty acid synthase (FASN) inhibitors. European Patent EP07110956.5.
40. Puig, T., C. Turrado, B. Benhamú, et al 2009. Novel Inhibitors of Fatty Acid Synthase with Anticancer Activity. Clin Cancer Res. 15: 7608-7615.
41. Relat, J. & T. Puig 2010. Frontiers in Drug Design and Discovery. 5: 211-235.